These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17549254)

  • 1. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.
    Aihara K; Azuma H; Akaike M; Ikeda Y; Sata M; Takamori N; Yagi S; Iwase T; Sumitomo Y; Kawano H; Yamada T; Fukuda T; Matsumoto T; Sekine K; Sato T; Nakamichi Y; Yamamoto Y; Yoshimura K; Watanabe T; Nakamura T; Oomizu A; Tsukada M; Hayashi H; Sudo T; Kato S; Matsumoto T
    J Clin Invest; 2007 Jun; 117(6):1514-26. PubMed ID: 17549254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin cofactor II as a novel vascular protective factor against atherosclerosis.
    Aihara K; Azuma H; Akaike M; Sata M; Matsumoto T
    J Atheroscler Thromb; 2009 Oct; 16(5):523-31. PubMed ID: 19729870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin cofactor II attenuates vascular remodeling in humans and mice.
    Aihara K
    Circ J; 2010 Aug; 74(8):1518-23. PubMed ID: 20671370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin cofactor II modulates the response to vascular injury.
    Tollefsen DM
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):454-60. PubMed ID: 17194895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular dermatan sulfate and heparin cofactor II.
    Tollefsen DM
    Prog Mol Biol Transl Sci; 2010; 93():351-72. PubMed ID: 20807652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice.
    Sumitomo-Ueda Y; Aihara K; Ise T; Yoshida S; Ikeda Y; Uemoto R; Yagi S; Iwase T; Ishikawa K; Hirata Y; Akaike M; Sata M; Kato S; Matsumoto T
    Hypertension; 2010 Sep; 56(3):430-6. PubMed ID: 20660821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis.
    Villa P; Aznar J; Vaya A; España F; Ferrando F; Mira Y; Estellés A
    Thromb Haemost; 1999 Sep; 82(3):1011-4. PubMed ID: 10494755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin cofactor II inhibits arterial thrombosis after endothelial injury.
    He L; Vicente CP; Westrick RJ; Eitzman DT; Tollefsen DM
    J Clin Invest; 2002 Jan; 109(2):213-9. PubMed ID: 11805133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
    Buchanan MR; Brister SJ
    Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice.
    Vicente CP; He L; Tollefsen DM
    Blood; 2007 Dec; 110(13):4261-7. PubMed ID: 17878401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role].
    Rossi EB; Duboscq CL; Kordich LC
    Medicina (B Aires); 1999; 59(1):95-104. PubMed ID: 10349131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin cofactor II levels are increased by the use of combined oral contraceptives.
    Mackie IJ; Segal H; Burren T; Gallimore M; Walshe KJ; Robinson G; Machin SJ
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):647-51. PubMed ID: 2133244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: comparison with the behaviors of prothrombin and fibrinogen.
    Hatton MW; Ross B; Southward SM; Dereske M; Hoogendoorn H; Blajchman MA; Richardson M
    J Lab Clin Med; 1999 Jan; 133(1):81-7. PubMed ID: 10385486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of frog and chicken cDNAs encoding heparin cofactor II.
    Colwell NS; Tollefsen DM
    Thromb Haemost; 1998 Nov; 80(5):784-90. PubMed ID: 9843172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
    Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
    Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan.
    Tanaka KA; Szlam F; Vinten-Johansen J; Cardin AD; Levy JH
    Thromb Haemost; 2005 Oct; 94(4):808-13. PubMed ID: 16270635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice.
    Vicente CP; He L; Pavão MS; Tollefsen DM
    Blood; 2004 Dec; 104(13):3965-70. PubMed ID: 15315969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji).
    Kondo S; Tokunaga F; Kario K; Matsuo T; Koide T
    Blood; 1996 Feb; 87(3):1006-12. PubMed ID: 8562924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand binding to thrombin exosite II induces dissociation of the thrombin-heparin cofactor II(L444R) complex.
    Han JH; Tollefsen DM
    Biochemistry; 1998 Mar; 37(9):3203-9. PubMed ID: 9485475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
    Sutherland JS; Bhakta V; Sheffield WP
    Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.